Entrada Therapeutics Inc (TRDA) support and resistance · P/E 12, rev $210.8M
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
This page maps Entrada Therapeutics Inc (TRDA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
TRDA currently screens at market cap $274.4M and trailing P/E 12.5. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new TRDA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the TRDA quote page for the session range and the stock page for the full model.
Not investment advice.